Immunocore’s (IMCR) Buy Rating Reiterated at HC Wainwright

Immunocore (NASDAQ:IMCR)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a research note issued on Wednesday,Benzinga reports. They presently have a $100.00 target price on the stock. HC Wainwright’s target price points to a potential upside of 251.86% from the stock’s previous close.

Several other research analysts have also recently issued reports on IMCR. Morgan Stanley reaffirmed an “equal weight” rating and issued a $35.00 price target on shares of Immunocore in a report on Friday, March 7th. Needham & Company LLC reaffirmed a “buy” rating and set a $71.00 target price on shares of Immunocore in a research report on Thursday, February 27th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, Immunocore presently has an average rating of “Moderate Buy” and a consensus target price of $65.64.

Immunocore Stock Performance

NASDAQ:IMCR opened at $28.42 on Wednesday. The company has a 50-day moving average of $30.14 and a 200-day moving average of $31.47. The firm has a market cap of $1.42 billion, a price-to-earnings ratio of -29.92 and a beta of 0.79. The company has a current ratio of 3.78, a quick ratio of 3.76 and a debt-to-equity ratio of 1.03. Immunocore has a twelve month low of $27.19 and a twelve month high of $66.00.

Institutional Trading of Immunocore

A number of hedge funds have recently made changes to their positions in the stock. Geode Capital Management LLC lifted its holdings in shares of Immunocore by 1.2% during the 4th quarter. Geode Capital Management LLC now owns 35,492 shares of the company’s stock valued at $1,047,000 after buying an additional 420 shares during the last quarter. GF Fund Management CO. LTD. bought a new stake in shares of Immunocore in the fourth quarter valued at about $25,000. China Universal Asset Management Co. Ltd. increased its position in shares of Immunocore by 12.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,393 shares of the company’s stock valued at $248,000 after purchasing an additional 960 shares during the period. NEOS Investment Management LLC raised its stake in shares of Immunocore by 10.9% in the 4th quarter. NEOS Investment Management LLC now owns 11,194 shares of the company’s stock valued at $330,000 after buying an additional 1,102 shares in the last quarter. Finally, Pier Capital LLC lifted its stake in Immunocore by 1.4% during the third quarter. Pier Capital LLC now owns 82,480 shares of the company’s stock worth $2,568,000 after purchasing an additional 1,174 shares during the period. 84.50% of the stock is owned by hedge funds and other institutional investors.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.